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Abstract
Background: In an earlier study we developed a unique strategy allowing us to specifically eliminate antigen-
specific murine B cells via their distinct B cell receptors using a new class of fusion proteins. In the present work we
elaborated our idea to demonstrate the feasibility of specifically addressing and eliminating human memory B cells.
Results: The present study reveals efficient adaptation of the general approach to selectively target and eradicate
human memory B cells. In order to demonstrate the feasibility we engineered a fusion protein following the
principle of recombinant immunotoxins by combining a model antigen (tetanus toxoid fragment C, TTC) for B cell
receptor targeting and a truncated version of Pseudomonas aeruginosa exotoxin A (ETA’) to induce apoptosis after
cellular uptake. The TTC-ETA’ fusion protein not only selectively bound to a TTC-reactive murine B cell hybridoma
cell line in vitro but also to freshly isolated human memory B cells from immunized donors ex vivo. Specific toxicity
was confirmed on an antigen-specific population of human CD27+ memory B cells.
Conclusions: This protein engineering strategy can be used as a generalized platform approach for the construction
of therapeutic fusion proteins with disease-relevant antigens as B cell receptor-binding domains, offering a promising
approach for the specific depletion of autoreactive B-lymphocytes in B cell-driven autoimmune diseases.
Keywords: B cell receptor, Targeted therapy, Recombinant fusion protein, Periplasmic protein expression,
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Background
B-lymphocytes play a major role in humoral immunity
and alterations in B cell development can cause certain
types of autoimmune diseases [1]. The secretion of self-
reactive antibodies by B-lymphocytes significantly con-
tributes to disease pathogenesis [2, 3]. In addition to the
secretion of autoantibodies, self-reactive B cells also
present autoantigens on their surface to stimulate
pathogenic T cells. In autoimmune diseases, the abnor-
mal recognition of autoantigens by self-reactive B cells
and T cells leads to severe tissue damage. Moreover, auto-
reactive B-lymphocytes are characterized by a deregulated
cytokine milieu reflecting the production of proinflamma-
tory cytokines such as interleukin-6 (IL-6), interferon-
gamma (IFN-γ), IL-4 and TGF-beta, all of which can
trigger dendritic cell migration, macrophage activation or
affect the regulatory role of T cells [4, 5]. Common strat-
egies for the treatment of autoimmune diseases include
the use of immunosuppressive agents such as steroids,
cytotoxic drugs or immunomodulatory agents to restore
homeostasis in the immune system and depress the auto-
immune response [2, 6]. These therapeutic agents offer
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symptomatic relief by inhibiting general inflammatory re-
sponses, but they do not exclusively target the misdirected
immune cells that are causing the disease. Many standard
therapeutic approaches affect all immune cells, regardless
of specificity, function or activation status. Current thera-
peutic strategies aim to eliminate various pathogenic cell
populations without targeting self-reactive memory B cells
directly [1, 7, 8]. With the help of a model antigen well
characterized in the human system we aim to demonstrate
the antigen-specific targeting of human B-lymphocytes via
their B cell receptor (BCR), which can offer a novel and
promising alternative approach for the treatment of auto-
immune diseases [9, 10]. We used protein engineering to
generate fusion proteins consisting of a cell-specific bind-
ing domain (an antigen or a fragment thereof) fused to an
effector domain (cytolytic or cytotoxic protein). The most
potent recombinant immunotoxins today are based on
truncated versions of Pseudomonas aeruginosa exotoxin A
(ETA’) [9–12]. The tetanus toxoid fragment C (TTC) is
often used as a model antigen because many people
worldwide are vaccinated with tetanus toxoid, and the
well-established TTC fragment is characterized by a fre-
quency of 0.01 % TTC-reactive memory B cells within the
B cell pool without a recent booster vaccination [13]. The
first requirement for a functional toxic fusion protein is
the specific binding to the BCR of self-reactive B cells,
followed by receptor-mediated internalization, the release
of the catalytic moiety from the endosomes for intracellu-
lar transport from the Golgi into the endoplasmic
reticulum, and finally its cytosolic release. This allows
ETA’ to exert its cytotoxic activity via ADP-ribosylation of
eukaryotic elongation factor 2 (eEF2), leading to efficient
inhibition of protein synthesis and ultimately to apoptosis
[14, 15]. The new fusion protein undergoes rapid
receptor-mediated endocytosis via the BCR [16]. We gen-
erated a TTC-ETA’ fusion protein for the specific deple-
tion of TTC-reactive B-lymphocytes isolated from human
blood. For straightforward staining purposes of TTC-
specific cell populations we developed a TTC-SNAP-tag
fusion protein allowing the covalent coupling of the fusion
protein to benzylguanine-conjugated fluorescent dyes to
examine binding kinetics at B cell surfaces [17]. Even if
expressed in two different expression systems, both pro-
teins bound specifically to TTC-reactive cells with similar
binding characteristics. Further, the TTC-ETA’ fusion pro-
tein demonstrated specific cytotoxicity towards human
TTC-reactive memory B cells ex vivo. The results of previ-
ous investigations performed by Volkman et al. suggested
that human TT-antibody responses can be inhibited
specifically in vitro using a TT-ricin conjugate. Using a
modified approach and a more elaborated read out this
work aims to confirm and quantify the selective depletion
of human TTC-specific memory B cells by an antigen-
ETA’ fusion protein. Based on the results of this study, we
believe that this concept has a platform character and can
be applied to generate powerful fusion proteins for immu-
notherapeutic approaches.
Methods
Cloning of expression vectors
The tetanus toxoid fragment C (TTC) DNA sequence
(GenBank accession no. FJ917402.1) was synthesized by
GeneArt® Gene Synthesis (Life Technologies, Darmstadt,
Germany) and included the restriction sites SfiI and
NotI. After digestion with these enzymes, the TTC DNA
sequence was ligated into the SfiI/NotI sites of pBM1.1
with and without the ETA’ sequence [18] and pMS [19]
(Fig. 1). Successful cloning was confirmed by colony
polymerase chain reaction and DNA sequencing.
Expression of TTC-ETA’ and TTC in Escherichia coli and
protein purification
Escherichia coli BL21 (DE3) cells (Novagen, Darmstadt,
Germany) were transformed with the TTC and TTC-
ETA’ encoding expression vectors and the corresponding
proteins were expressed into the periplasm under os-
motic stress in the presence of compatible solutes [20].
The protein was purified from the periplasmic fraction
by immobilized metal-ion affinity chromatography
(IMAC) using a Nickel-Sepharose (Ni-NTA) Superflow
Cartridge (Qiagen, Hilden, Germany) on the ÄKTApuri-
fier system (GE Healthcare Life Sciences, Freiburg,
Germany) followed by a size-exclusion chromatography
using a Superdex 200 (GE Healthcare). The TTC pro-
teins were eluted into phosphate buffered saline (PBS,
pH 7.4) and concentrated using Vivaspin 6 columns
(Sartorius, Goettingen, Germany). The proteins were
passed through a 0.22-μm sterile filter (Nalgene, Roskilde,
Denmark) and analyzed by sodium dodecylsulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) as previously
described [21]. After gel staining with Coomassie Brilliant
Blue, the protein concentration was estimated using AIDA
Image Analyzer (Raytest GmbH, Straubenhardt, Germany)
against 0.25-3 μg standards of bovine serum albumin
(BSA). Unstained gels were blotted onto nitrocellulose
membranes and probed with a primary anti-penta-his anti-
body diluted 1:5000 (Qiagen, Hilden, Germany; Catalogue
number: 34660) and an alkaline phosphate (AP)-coupled
goat-anti-mouse secondary antibody also diluted 1:5000
(Dianova, Hamburg, Germany; Catalogue number: 115-
055-020).
Expression of SNAP-TTC in HEK293T cells
Human embryonic kidney cells (HEK293T, ATCC,
Wesel, Germany, CRL-11268) were cultured under
standard conditions (RPMI 1640 medium, 10 % v/v fetal
calf serum (FCS), 100 U/ml penicillin, 100 mg/ml
streptomycin, 37 °C, 5 % CO2) and transfected with the
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pMS expression vectors using Roti®-Fect (Carl Roth,
Karlsruhe, Germany) according to the manufacturer’s
instructions. Briefly, 2 μg of DNA was mixed with 2 μl
of Roti®-Fect and applied to the cells for 3 h. The cul-
tures were then supplemented with 100 ng/ml Zeocin®
(Invitrogen, Carlsbad, USA) for selection. The super-
natant was collected from the transfected HEK293T cells
and the protein was purified by IMAC as described
above. After overnight dialysis against 1 x PBS at 4 °C,
the SNAP-TTC protein was passed through a 0.22-μm
sterile filter (Nalgene, Roskilde, Denmark). The protein
concentration was determined using the AIDA Image
Analyzer as described above.
Coupling SNAP-TTC to the fluorescent dye
Purified SNAP-TTC was conjugated to the BG-modified
fluorescent dyes SNAP-surface® Alexa Fluor® 647 (New
England Biolabs, Frankfurt am Main, Germany; Catalogue
number: S9136S) and SNAP-surface® Alexa Fluor® 488
(New England Biolabs; Catalogue number: S9129S) as pre-
viously described [17]. Briefly, 1 μg SNAP-TTC protein
was mixed with 2 nmol BG-647 or BG-488 solution
prepared from a 50 nmol stock and incubated for 1 h at
room temperature. Samples were taken to determine the
coupling efficiency by SDS-PAGE and the fluorescence
signal was detected using the CRi Maestro imaging
system with appropriate filter sets (Perkin Elmer,
Waltham, MA, USA).
Cultivation of hybridoma cells and cell binding analysis
by flow cytometry
TTC-reactive 5E4 hybridoma cells (kindly provided by
Prof. Dr. M. Shapiro, Rockville, USA) and myelin oligo-
dendrocyte glycoprotein (MOG)-reactive 8.18-C5 hy-
bridoma cells (kindly provided by Prof. C. Linington,
Glasgow, UK) were cultured under standard conditions
(RPMI 1640 medium, 10 % FCS, 100 U/ml penicillin,
100 mg/ml streptomycin, 37 °C, 5 % CO2). The binding
of TTC fusion proteins to 5 × 105 TTC-reactive hybrid-
oma cells was evaluated by flow cytometry using a BD
FACSVerse flow cytometer (Becton Dickinson, Heidelberg,
Germany) and BD FACSuite analysis software. Briefly, the
cells were incubated with 100 nM purified TTC fusion
proteins for 20 min and then with 1 μg/ml anti-His5
AlexaFluor 488 antibody (Cat. no. 35310, Qiagen, Hilden,
Germany) for 20 min, in each case on ice with intermediate
washes in 1.8 ml 1 x PBS. Dose-dependent binding of
TTC-ETA’ was analyzed on TTC-reactive 5E4 hybridoma
cells. MOG-reactive 8.18-C5 hybridoma cells were used as
a negative control. Briefly, 2 x 105 target cells were incu-
bated with various concentrations (1–400 nM) of TTC-
ETA' followed by incubation with 1 μg/mL Penta-His Alexa
Fig. 1 Illustration of the prokaryotic and eukaryotic expression vectors. The synthetic tetanus toxoid fragment C (TTC) DNA sequence was cloned
into the prokaryotic expression vector pBM and the eukaryotic expression vector pMS using the restriction sites SfiI and NotI. a Prokaryotic
expression vector pBM-TTC-ETA’. pelB = signal sequence for protein secretion into the periplasm; 10xHis-tag = polyhistidin-sequence for detection
and purification of recombinant proteins; A = antigen fragment; ETA’ = deletion mutant of Pseudomonas aeruginosa exotoxin A; f1 ori = origin of
replication for production of single-stranded DNA by M13-helper phage; kanR = kanamycin resistance gene for he selection of transformed cells;
ori(3331) = origin of replication; lacI = Lac repressor; T7 prom + Lac op. = IPTG-inducible promotor + Lac-Operator. b Eukaryotic expression vector
pMS-L-SNAP-TTC. pCMV = constitutive active promotor of the cytomegalovirus; Ig-κ-Leader =murine signal sequence for protein secretion into
the cell culture supernatant; Myc/His-tag = c-myc-epitope for detection/polyhistidin-tag for detection and purification; eGFP = enhanced green
fluorescent protein; BGH = Bovine growth hormone (BGH) polyadenylation signal, ZeoR = Zeocin® resistance gene for the selection of transfected
cells, pSV40 = early SV40-promotor, SV40 replication origin (ORI); polyA = polyadenylation signal, ColE1 origin = bacterial origin of replication;
AmpR = ampicillin resistance gene for the selection of transformed Escherichia coli
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Fluor 488 Conjugate antibody (Cat. no. 35310, Qiagen, Hil-
den, Germany). Cells were washed twice with 1x PBS in
each step and finally eluted in FACS buffer. The binding ac-
tivity of TTC-ETA' was analyzed on a BD FACSVerse flow
cytometer (Becton Dickinson) using the BD FACSuite ana-
lysis software (Becton Dickinson). Mean values of three in-
dependent measurements were normalized and fitted using
the GraphPad Prism v5 software (GraphPad Software, Inc.,
La Jolla, CA, USA).
Hybridoma cell viability assay
Hybridoma 5E4 and 8.18-C5 cells (1 x 104 cells/well)
were incubated with serially diluted TTC-ETA’ and TTC
proteins in cell culture media (RPMI 1640, 10 % v/v
FCS) at 37 °C and 5 % CO2 for 72 h. Cell viability was
determined by adding XTT/phenazine methosulfate in
50 μl RPMI medium and incubating as above for 4 h.
Absorbance was measured at 450 nm and 630 nm (refer-
ence wavelength) on a BioTek ELISA reader (Bad
Friedrichshall, Germany). Results are presented as the
means of three independent experiments with the corre-
sponding standard deviations. The half maximal inhibi-
tory protein concentration (EC50) was calculated
relative to untreated control cells. Raw data were fitted
using the GraphPad Prism v5 software (GraphPad
Software, Inc., La Jolla, CA, USA).
Isolation of B-lymphocytes
For enzyme-linked immunospot (ELISPOT) assays CD27+
memory B cells were isolated from leukocyte filters
obtained from tetanus-vaccinated blood donors. The local
ethics committee approved this procedure. The donors
gave written informed consent and were asked for their
status of vaccination. First, total B cells were isolated by
negative selection using the RosetteSep™ Human B Cell
Enrichment Cocktail (STEMCELL Technologies SARL,
Grenoble, France) and subsequent density gradient centri-
fugation with Ficoll-Paque PLUS (GE Healthcare, Munich,
Germany). After two washing steps with PBS containing
0.5 % BSA (Sigma-Aldrich, Taufkirchen, Germany) the B
cells were immediately labeled with CD27 MicroBeads
(Miltenyi Biotec, Bergisch Gladbach, Germany; Catalogue
number: 130-051-601) and subsequently isolated using LS
columns and a MidiMACS Separator according to the
manufacturer’s instructions (Miltenyi Biotec). Thereafter,
the isolated CD27+ memory B cells were incubated at a
concentration of 105 cells per ml in RPMI 1640 medium
supplemented with 10 % v/v FCS, 100 U/ml penicillin and
100 mg/ml streptomycin (all from Life Technologies
GmbH, Darmstadt, Germany) on a 96-well round-
bottomed plate (Greiner Bio-One, Frickenhausen,
Germany) with 2.5 μg/ml CpG oligodeoxynucleotide 2006
(5’-TCG TCGTTTTGTCGTTTTGTCGTT-3’, TIB Mol-
Biol, Berlin, Germany) and 50 ng/ml interleukin (IL)-21
(Life Technologies GmbH, Darmstadt, Germany). After
polyclonal activation with the TLR-9 agonist CpG and IL-
21, 10 nM TTC or TTC-ETA was added to the culture
medium on day 2. On day 4, activated cells were harvested
and ELISPOT assays were carried out to determine the
frequencies of IgG, anti-tetanus toxoid (TT) IgG as well as
anti-TTC specific IgG antibody secreting cells (ASCs). For
flow cytometric analyses CD19 MicroBeads (Miltenyi
Biotec; Catalogue number: 130-097-055) instead of CD27
MicroBeads were used for positive selection and periph-
eral blood mononuclear cells (PBMCs) were isolated from
a donor 6 and 14 days after booster vaccination with tet-
anus toxoid to determine the binding of the TTC fusion
protein to ex vivo plasma cells and memory B cells,
respectively. Briefly, PBMCs were isolated by density
gradient centrifugation with Ficoll-Paque PLUS (GE
Healthcare) and stained for TTC-specific CD27++CD38++
plasma cells or CD27+ memory B cells.
Binding analysis of the TTC fusion protein to
B-lymphocytes by flow cytometry
The staining was performed with the following mono-
clonal antibodies against the human B cell specific
surface markers CD19 (Becton Dickinson; Catalogue
number: 560911), CD27 (Becton Dickinson; Catalogue
number: 337169), CD38 (Becton Dickinson, Catalogue
number: 345806) and biotinylated IgD (Becton Dickinson;
Catalogue number: 555777) in combination with strepta-
vidin Alexa-Fluor 680 (Life Technologies; Catalogue num-
ber: S21378) in combination with the recombinant TTC
protein followed by an Alexa Fluor 488-conjugated anti-
penta-his antibody (Qiagen; Catalogue number: 35310).
For comparison, a FITC-labeled TTC peptide (List
Biological Laboratories, Inc., CA, USA) was used. For the
intracellular TTC staining saponin was added. In the case
of surface staining dead cells were excluded by labeling
with 220 nM 4’,6-diamidino-2-phenylindole (DAPI; Life
Technologies). Flow cytometry was carried out using
a FACSCanto™ with FACS DIVA Software (Becton
Dickinson) and the results were analyzed using the
FlowJo software (Treestar, Ashland, OR, USA).
Quantitation of TT- and TTC-specific ASCs by ELISPOT
after polyclonal activation of CD27+ memory B cells
After polyclonal activation with the TLR-9 agonist CpG
and IL-21 for 4 d, we carried out ELISPOT assays to de-
termine the frequency of IgG+ anti-tetanus toxoid (TT)
and anti-TTC specific ASCs. Based on the results of the
hybridoma cell viability assay, on day 2 of cultivation,
the memory B cells were treated with 10 nM TTC or
TTC-ETA’. To determine the frequencies of total ASCs,
high-binding 96-well ELISA plates (Greiner Bio-One)
were pre-coated overnight at 4 °C with goat anti-human
kappa and lambda antibodies (SouthernBiotech, AL,
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USA; Catalogue numbers: SBA1050-04, SBA1060-04).
To determine the frequencies of tetanus-specific ASCs,
high-binding 96-well ELISA plates were pre-coated with
20 Lf/ml tetanus toxoid (Statens Serum Institute,
Copenhagen, Denmark) or with 20 μg/ml TTC protein.
After three washes with 150 μl/well PBS plus 0.5 % BSA,
the plates were blocked with 200 μl/well PBS containing
3 % BSA and 5 % FCS for 1 h at 37 °C in a 5 % CO2
atmosphere. The obtained cells were titrated and plated
in duplicates in the following 10 dilutions: 5–1,000 cells/
well for total IgG and 2,000-100,000 cells/well for TT and
TTC IgG ELISPOTs. After incubating for 8 h at 37 °C, the
plates were washed six times with 150 μl/well PBS. Spots
were visualized using AP-conjugated goat anti-human IgG
(SouthernBiotech; Catalogue number: SBA1030-04) for
1 h at 37 °C in a 5 % CO2 atmosphere, followed by
adding the 2-amino-2-methyl-1-propanol (AMP) buffer
supplemented with 5-bromo-4-chloro-3-indolyl-phos-
phate (BCIP)/nitroblue tetrazolium (NBT). After
counting the spots, the frequencies of TT and TTC
IgG-secreting ASCs were calculated for each individual.
Statistical analysis
Statistical analyses were based on at least three inde-
pendent series of experiments in triplicates. The two-
tailed Student’s t-test was used for statistical analysis. A
P value of less than 0.05 was considered statistically
significant. Calculations were performed using GraphPad
Prism v5 software.
Results
Expression of TTC fusion proteins
The prokaryotic and eukaryotic expression vectors
containing the TTC cell-binding domain were sequenced
to verify the correct format of the fusion domains. The
pBM expression vectors (Fig. 1a) were then introduced
into Escherichia coli strain BL21 (DE3) and the pMS ex-
pression vector (Fig. 1b) was used for the transient
transfection of HEK293T cells. TTC and TTC-ETA’
proteins were periplasmically expressed in E. coli BL21
(DE3) cells under osmotic stress conditions in the pres-
ence of compatible solutes. After purification by IMAC
using a Ni-Sepharose Superflow cartridge followed by
size exclusion chromatography, we achieved yields of up
to 1.1 mg TTC (MW: 55 kDa) and 1.8 mg TTC-ETA’
(MW: 95 kDa) per liter of bacterial culture. The purified
fusion proteins were analyzed by SDS-PAGE and west-
ern blot using a mouse anti-His6 monoclonal antibody
(Additional file 1: Figure S1). The SNAP-TTC fusion
protein expressed in transfected HEK293T cells was
secreted into the cell culture supernatant and purified by
IMAC using a Ni-Sepharose Superflow cartridge as
above, resulting in a yield of 6 mg per liter of cell culture
supernatant. The protein was analyzed by SDS-PAGE
and the corresponding western blot confirmed the ex-
pression of SNAP-TTC (data not shown). The SNAP-
TTC protein was successfully coupled to the fluorescent
dyes BG-488 or BG-647 and detected using the CRi
Maestro imaging system (Fig. 2a). The SDS polyacryl-
amide gel was then stained with Coomassie Brilliant
Blue and we confirmed that the protein bands matched
the corresponding fluorescence signals (Fig. 2b).
Binding of TTC and TTC-ETA’ to hybridoma cells
TTC-ETA’ selectively targets TTC-reactive hybridoma
cells and TTC-reactive memory B cells by binding to the
TTC-reactive BCR. This binding activity is necessary for
the biological function of the protein and was confirmed
by investigating the ability of the fusion protein to bind
TTC-reactive 5E4 hybridoma cells, which express the
membrane-bound form of the BCR. The quantity of pro-
tein bound to the cell surface was determined by flow
cytometry using an Alexa Fluor 488-conjugated anti-
penta-his antibody. This confirmed that both TTC and
TTC-ETA’ bound to the TTC-reactive hybridoma cells,
whereas no binding was observed on the control cell line
(MOG-specific hybridoma 8.18-C5 cells) as shown in
Fig. 3a and b. Both hybridoma cell lines showed similar
amounts of B cell receptors on their cell surfaces
(approx. 1500 receptors per cell) as determined by flow
cytometry (data not shown). Coupling SNAP-TTC to
BG-647 did not affect the functionality of the protein,
and we were able to detect specific binding of the pro-
tein to the surface of TTC-reactive hybridoma cells but
not to the control hybridoma cells by flow cytometry
(Fig. 3c and d). The TTC-ETA’ fusion protein exhibited a
concentration-dependent binding to the TTC-reactive
hybridoma cell line 5E4 compared to the control hybrid-
oma cell line 8.18-C5 as shown in Fig. 4a and b.
Viability of hybridoma cells following treatment with TTC
fusion proteins
After confirming the binding of the TTC fusion protein to
the BCR on the surface of TTC-reactive 5E4 hybridoma
cells, we investigated the toxicity of the TTC-ETA’ fusion
protein in vitro using an XTT cell viability assay. TTC-ETA’
showed specific and dose-dependent toxicity towards TTC-
reactive 5E4 hybridoma cells with a half inhibitory protein
concentration (EC50) of 1.3 ± 0.4 nM, but they showed no
toxicity towards control hybridoma cells (Fig. 5a). Further-
more, the TTC protein alone showed no toxicity towards
either of the hybridoma cell lines (Fig. 5b).
Binding analysis of TTC fusion proteins to B-lymphocytes
Next, we determined the binding capacity of the SNAP-
TTC-BG-647 protein to polyclonally activated CD19+ B
cells isolated from leukocyte filters of vaccinated blood
donors by flow cytometry. Figure 6 demonstrates that the
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frequencies of TTC-specific B cells remain low at day 4
after polyclonal activation (intracellular staining, Fig. 6b)
compared to residual signals of the control B cells (surface
staining, Fig. 6a). Since the frequencies of TTC-specific B
cells were extremely low after polyclonal activation in do-
nors without a recent booster vaccination (Fig. 6b), the
binding of the TTC fusion protein was additionally verified
on plasma cells and memory B cells isolated at day 6 and
day 14 from a blood donor vaccinated recently, respectively.
The samples were exposed to the recombinant TTC pro-
tein followed by an Alexa Fluor 488-conjugated anti-penta-
his secondary antibody. Flow cytometry showed that
tetanus-reactive CD27+ memory B cells (surface staining,
Fig. 7a) as well as tetanus-reactive CD27++CD38++ plasma
Fig. 2 Fluorescent in-gel detection of SNAP-TTC labeled with different dyes. a SDS-PAGE of SNAP-TTC fusion protein labeled with SNAP-Surface® Alexa
Fluor® 488 (2) or BG-647 (3), respectively. Fluorescence signals were visualized using the Maestro CRi in vivo imaging system with the appropriate filter
set. b Coomassie-stained SDS gel from (a). The stained protein bands correspond to the measured fluorescence signals from (a). (1) prestained protein
marker, broad range (NEB), (2) SNAP-TTC-SNAP-Surface® Alexa Fluor® 488, (3) SNAP-TTC-BG647, (4) uncoupled SNAP-TTC protein
Fig. 3 Binding analysis of recombinant TTC-based proteins to TTC-reactive hybridoma cells. Equimolar amounts (100 nM) of TTC (c) and TTC-ETA’
(d) were used for binding analysis to the TTC-reactive hybridoma cell line 5E4 (a) compared to the control hybridoma cell line 8.18-C5 (b). Detection of
bound proteins was carried out using an Alexa Fluor® 488-coupled anti-His5 antibody. Staining with Alexa Fluor 488-coupled anti-His5 antibody
(b) and unstained cells (a) served as controls. Binding analysis of 100 nM SNAP-TTC coupled to the SNAP-Surface® 647 fluorescence dye (b) to 5E4
hybridoma cells (c) and to the control hybridoma cell line 8.18-C5 (d). Unstained cells served as control (a)
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cells (intracellular staining, Fig. 7c) were detectable within
the peripheral B cell pool shortly after booster vaccination.
The frequencies of TTC-reactive memory B cells and
plasma cells detected using the recombinant TTC protein
was comparable to the use of the commercial FITC-
conjugated TTC protein (Fig. 7b and d). TTC bound specif-
ically to TTC-reactive memory B cells and plasma cells
within the peripheral B cell pool.
Cytotoxic activity of the recombinant TTC-ETA’ protein on
polyclonally activated memory B cells
Having confirmed the targeting of TTC-reactive memory
B cells, we next set out to measure the depletion effects of
the TTC-ETA’ protein. Therefore, CD27+ memory B cells
were activated polyclonally to develop into antibody-
secreting cells (ASCs) and were treated on day 2 of culti-
vation with 10 nM of recombinant TTC or TTC-ETA’.
Next, ELISPOT analyses were performed to determine the
frequency of all IgG-secreting cells as well as the TT-
specific and TTC-specific IgG-secreting cells. The ASCs
secreted IgG antibodies at comparable frequencies after
treatment with TTC or TTC-ETA’ (Fig. 8a). The ELISPOT
assays were carried out with commercial tetanus toxoid
(TT) as the coating agent. When TTC protein was added
to the cultures as the control protein, the ASCs secreted
the TT-IgG antibodies at a frequency of 0.7 ± 0.6 %
(Fig. 8b). Following the treatment with TTC-ETA’ the
frequency of TT-IgG antibodies secreted by the ASCs
declined to 0.4 ± 0.3 % (Fig. 8b). When tetanus toxoid
fragment C (TTC) was used as the ELISPOT coating
Fig. 4 Dose-dependent binding analysis of the recombinant fusion protein TTC-ETA’ on hybridoma cells. Various concentrations (1–400 nM) of
TTC-ETA’ were used to determine a dose-dependent binding activity on TTC-reactive hybridoma cell line 5E4 (a) and to exclude specific binding
to the control hybridoma cell line 8.18-C5 (b). The detection of bound protein was carried out by flow cytometry using a Penta-His Alexa Fluor
488 Conjugate antibody. Measurements were performed in triplicates (n = 3); error bars indicate SD. The recombinant TTC-ETA’ exhibits a dosede-
pendent binding on the target hybridoma cell line 5E4, whereas no binding could be determined on the control hybridoma cell line 8.18-C5
Fig. 5 Cytotoxic activity of recombinant TTC-ETA’ on hybridoma cells. The hybridoma cell lines 5E4 (▼; n = 4) and 8.18-C5 (■; n = 3) were incubated
with serial dilutions of TTC-ETA’ (a) and TTC (b) in complete RPMI 1640 cell culture medium. After incubation at 37 °C and 5 % CO2 for 72 h, the cells
were refreshed with 50 μl RPMI 1640 medium containing XTT/phenazine methosulfate and incubated for another 4 h. Absorbance was measured at
450 nm and 630 nm on an ELISA reader. The half maximal inhibitory protein concentration (EC50) relative to untreated control cells was calculated
using GraphPad Prism software. The recombinant TTC-ETA’ exhibits a dose-dependent cytotoxicity on the target hybridoma cell line 5E4 with an EC50of
1.3 nM± 0.4 nM but has no effect on the control cell line 8.18-C5. These data represent the mean ± SD of three independent experiments performed in
triplicates. *, P< 0.05; ** , P< 0.01; P< 0.001 versus control cells
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agent, we observed a small increase in the frequencies
of general IgG antibodies following TTC-ETA’ treat-
ment (Fig. 8c). The depletion effect of the TTC-ETA’
protein was confirmed by lower frequencies of secreted
TTC-IgG antibodies decreasing significantly from 0.1 ±
0.12 to 0.02 ± 0.03 % (p = 0.0156) compared to treat-
ment with the control protein TTC (Fig. 7d).
Discussion
The bacterial pBM1.1 and the eukaryotic pMS expres-
sion vectors are platforms that allow the convenient
insertion of sequences to genetically fuse antibody frag-
ments or peptide-based binding moieties to cytotoxic
effector domains. We were able to generate immuno-
toxin expression vectors with TTC as the cell-binding
Fig. 6 Binding analysis of recombinant SNAP-TTC-BG647 on polyclonally activated CD19+ B cells. CD19+ B cells were isolated from leukocyte filters by
density gradient centrifugation and magnetic cell separation with anti-CD19 beads. Isolated B cells were activated by adding 2.5 μg/ml CpG and
50 ng/ml IL-21 to the cell culture medium. On day 4 of cultivation, the cells were analyzed by flow cytometry. Surface a and intracellular b staining
with the recombinant SNAP-TTC-BG 647 (1:25) was performed
Fig. 7 Binding analysis of recombinant TTC and TTC-FITC on isolated PBMCs. Surface staining of CD27+ memory B cells (a) and intracellular staining of
CD27++CD38++ plasma cells (c) using recombinant TTC (10 nM) and anti-His5 Alexa Fluor 488 antibody (1:100). Surface staining of CD27+ memory B
cells (b) and intracellular staining of CD27++CD38++ plasma cells (d) using a FITC-coupled TTC peptide (1:25)
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domain with or without ETA’ as the cytotoxic domain.
TTC and TTC-ETA’ were expressed in bacteria and
purified by IMAC, with a yield comparable to similar
fusion proteins expressed in earlier investigations, such
as MOG-ETA’ [10]. Periplasmic expression of fusion
proteins in bacteria avoids the labor-intensive process
of refolding proteins accumulated in inclusion bodies.
Expression of the fusion proteins TTC and TTC-ETA’
was scalable, and under the applied osmotic stress con-
ditions we found that the immunotoxin was more than
95 % functional [11, 20]. The TTC-reactive hybridoma
cell line provides a simple and reliable test system for
the TTC-ETA’ fusion protein as a “model immuno-
toxin”. The recombinant TTC-ETA’ protein demon-
strated its functionality by specifically binding to its
respective hybridoma cell line and displaying a dose-
dependent cytotoxicity (Fig. 3). The SNAP-tag pro-
motes the rapid and efficient coupling of reagents
such as fluorescent dyes, and the resulting fluorescent
SNAP-tag conjugates can be used as diagnostic tools
because the function of the SNAP-tag fusion partner
is not affected [17, 22, 23]. Here, we demonstrated
the functionality of the SNAP-TTC-BG-647 protein
by specific binding to TTC-reactive hybridoma (Fig. 3)
and human memory B cells (Fig. 6) which was comparable
to the binding activity of TTC and TTC-ETA'. Investigat-
ing TTC-specific ASCs after polyclonal activation of
human memory B cells by ELISPOT we confirmed the
specific binding of the TTC fusion proteins to CD27+
memory B cells isolated from human blood and their sub-
sequent depletion resulting in a failure to generate TTC-
specific ASCs after polyclonal activation and plasma cell
differentiation. Compared to earlier developments by
Volkman et al. [24] or Grailer et al. [25] we established an
effective fusion protein expression platform enabling us to
produce protein therapeutics in high yields and with
homogeneous purity. Using this technology, we were able
to show that a peptide fragment of an antigen recognized
by the BCR can be used as the cell-binding component of
a cytotoxic fusion protein, ensuring that the immunotoxin
targets an antigen-specific B cell population without af-
fecting the entire B cell pool. Both cell types (hybridoma
Fig. 8 Cytotoxic activity of TTC-ETA’ on TTC-specific polyclonally activated memory B cells. Frequencies of IgG (a, c), of tetanus toxoid (TT)- (b) and of TTC-
specific IgG (d) antibody-secreting cells (ASC) incubated with recombinant TTC (10 nM) or TTC-ETA’ (10 nM) protein on day 2 of polyclonal activation. The
data are the results of 5 independent experiments using TT-coated plates (b) and 7 experiments using TTC-coated plates (d) and the corresponding total
IgG ELISPOT assay (a, c). Statistical analysis was performed using the Wilcoxon matched-pairs signed rank test
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cells and ASCs obtained from polyclonally activated
memory B cells) produce soluble antibodies that can
encounter and intercept the TTC fusion proteins in
vitro, ex vivo and in vivo. Nevertheless, the TTC-ETA’
fusion protein showed dose-dependent cytotoxicity to-
wards TTC-reactive 5E4 hybridoma cells with an EC50
value of 1.4 nM (Fig. 5). For TTC-ETA’, we determined
a half maximal effective concentration (EC50) value
that is comparable to related fusion proteins based on
an allergen fragment [19] or a major autoantigen in
multiple sclerosis [10]. The labeling of polyclonally acti-
vated CD19+ B cells by the SNAP-TTC-BG-647 protein
showed that the number of tetanus-reactive B cells de-
clines if a long time has elapsed since the last tetanus
vaccination (Fig. 6). Self-reactive plasma cells are also
rarely observed in the peripheral blood even in patients
with active autoimmune disease [26] and data about
self-reactive memory B cells in these patients is limited.
Provided that their frequency is comparable with that
of TTC-reactive B cells in vaccinated controls, it seems
challenging to isolate and study these cells in patients
with disease- or treatment-related lymphopenia. Hence,
future investigations should consider strategies of poly-
clonal activation and subsequent enrichment of these
memory B cells to raise their abundance. And for some
autoantigens the use of animal models seems still inev-
itable. We found that exposing the activated human
memory B cell pool to 10 nM TTC-ETA’ resulted in an
80 % inhibition of generated TTC-reactive IgG secret-
ing cells compared to the control treatment with the
TTC protein lacking a toxic domain (Fig. 8). These re-
sults clearly indicate that only the TTC-ETA’ fusion
protein significantly affected the generation of TTC-
reactive ASCs. Self-reactive memory B cells have been
shown to be resistant to many standard therapeutic
approaches [3]. They represent plasma cell precursors
that are easy to activate [27].
We confirmed that it is possible to target antigen spe-
cific human memory B cells using novel cytotoxic fusion
proteins containing part of the antigen as a cell-binding
domain. This novel strategy will facilitate the develop-
ment of targeted therapies based on the specific charac-
teristics of each patient.
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Conclusions
This protein engineering strategy can be used as a gener-
alized platform approach for the construction of thera-
peutic fusion proteins with disease-relevant antigens as
B cell receptor-binding domains, offering a promising
approach for the specific depletion of autoreactive B-
lymphocytes in B cell-driven autoimmune diseases.
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Additional file 1: Figure S1. Expression and purification of TTC-ETA' and
TTC. Coomassie-stained SDS gel (left) and corresponding western blot (right)
of TTC-ETA' (1; 95 kDa) and TTC (2; 55 kDa) produced by bacterial expression
under osmotic stress conditions and purified by immobilized metal ion affinity
chromatography and subsequent size exclusion chromatography.
Proteins were separated by SDS polyacrylamide gel electrophoresis on
a 12 % polyacrylamide gel and detected using a primary anti-penta-his
antibody diluted (1:5000) and an alkaline phosphate (AP)-coupled goat-
anti-mouse secondary antibody (1:5000). (TIF 10310 kb)
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